Author details

Full Name

Stephan A Grupp

Affiliation

ORCID

Career Start Year

1985

Papers

266

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37481241	INSPIRED Symposium Part 1: Clinical Variables Associated with Improved Outcomes for Children and Young Adults treated with Chimeric Antigen Receptor T cells for B cell Acute Lymphoblastic Leukemia.		2023
36351239	Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy.	Blood	2023
35482927	Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells.	Blood Adv	2023
36399695	Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial.	J Clin Oncol	2023
36255409	Characterization of Leukemic Resistance to CD19-Targeted CAR T-cell Therapy through Deep Genomic Sequencing.	Cancer Immunol Res	2023
35776199	A novel antibody-TCR (AbTCR) T-cell therapy is safe and effective against CD19-positive relapsed/refractory B-cell lymphoma.	Journal of Cancer Research and Clinical Oncology	2023
37607096	Chimeric Antigen Receptor T Cell Manufacturing on an Automated Cell Processor.		2023
37721859	Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients.		2023
37718626	Bone marrow fibrosis is associated with non-response to CD19 CAR T-cell therapy in B-acute lymphoblastic leukemia.		2023
37863087	Driving two chimeric antigen receptors (CARs) in a row to reduce antigen escape in B-cell acute lymphocytic leukaemia.		2023
37407140	Defibrotide prophylaxis for prevention of sinusoidal obstruction syndrome - Authors' reply.		2023
36898064	Reply to W.H. Tong et al.		2023
37142257	The utility of biomarkers in acute GVHD prognostication.		2023
37199022	Impact of diagnostic and end-of-induction Curie scores with tandem high-dose chemotherapy and autologous transplants for metastatic high-risk neuroblastoma: A report from the Children's Oncology Group.		2023
37315175	Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD.		2023
37001534	Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (HARMONY): a randomised, multicentre, phase 3 trial.		2023
36610491	Automation of Hematopoietic Cell Transplantation Outcomes Reporting Leads to Dramatic Reduction in Errors Reported to Real-World Data Registry.		2023
37235690	Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease.		2023
37231094	Prevention of veno-occlusive disease/sinusoidal obstruction syndrome: a never-ending story and no easy answer.		2023
37499029	In vivo hematopoietic stem cell modification by mRNA delivery.		2023
34871373	Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CARÂ T-cell therapy.	Blood	2022
35976030	Correction for Bagashev et al., "CD19 Alterations Emerging after CD19-Directed Immunotherapy Cause Retention of the Misfolded Protein in the Endoplasmic Reticulum".	Molecular and Cellular Biology	2022
35838646	Statistical Considerations for Analyses of Time-To-Event Endpoints in Oncology Clinical Trials: Illustrations with CAR-T Immunotherapy Studies.	Clinical Cancer Research	2022
35705524	Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19.	Clin Cancer Res	2022
35834728	Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy.	Blood Adv	2022
36075914	Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma.	Nature Communications	2022
35560156	Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL.	Blood	2022
35422096	Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia.	Leukemia	2022
35675405	Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL.	Sci Adv	2022
35019853	Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia.		2022
35015687	Potential Role of IFNÎ³ Inhibition in Refractory Cytokine Release Syndrome Associated with CAR T-cell Therapy.		2022
34767461	Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL.	J Clin Oncol	2022
34872106	Unrelated donor Î±/Î² T cell- and B cell-depleted HSCT for the treatment of pediatric acute leukemia.	Blood advances	2022
34471240	Mesenchymal stromal cell therapy induces high responses and survival in children with steroid refractory GVHD and poor risk biomarkers.	Bone Marrow Transplantation	2021
33750075	Improving and Maintaining Responses in Pediatric B-Cell Acute Lymphoblastic Leukemia Chimeric Antigen Receptor-T Cell Therapy.	Cancer journal (Sudbury, Mass.)	2021
34061452	Tisagenlecleucel for treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia.	Pediatric Blood and Cancer	2021
34006631	Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells.	J Immunother Cancer	2021
34156874	Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia.	J Clin Oncol	2021
33888899	Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells.	Nat Med	2021
33881465	Absolute lymphocyte count proliferation kinetics after CAR T-cell infusion impact response and relapse.	Blood advances	2021
33830028	Immune Reconstitution Following TCRÎ±Î²/CD19-Depleted Hematopoietic Cell Transplantation for Hematologic Malignancy in Pediatric Patients.	Transplantation and Cellular Therapy	2021
33608691	Will allogeneic CAR T cells for CD19 malignancies take autologous CAR T cells 'off the shelf'?	Nature Reviews Clinical Oncology	2021
34094824	CAR-T cells: Early successes in blood cancer and challenges in solid tumors.	Acta Pharmaceutica Sinica B	2021
33823167	Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1.	Transplant Cell Ther	2021
34028986	A safety and feasibility trial of <sup>131</sup> I-MIBG in newly diagnosed high-risk neuroblastoma: A Children's Oncology Group study.	Pediatr Blood Cancer	2021
33820778	Integrative Bulk and Single-Cell Profiling of Premanufacture T-cell Populations Reveals Factors Mediating Long-Term Persistence of CAR T-cell Therapy.	Cancer Discov	2021
34353848	Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia.	J Immunother Cancer	2021
33496754	Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy.	Blood advances	2021
33495553	Beyond the storm - subacute toxicities and late effects in children receiving CAR T cells.	Nat Rev Clin Oncol	2021
33283989	CRISPR-Cas9 Gene Editing for Sickle Cell Disease and Î²-Thalassemia.	N Engl J Med	2021